Key Takeaways ABT's Q2 revenues are projected at $11.07B, up 6.7% year over year; EPS is estimated to rise 9.6% to $1.25. ABT's Medical Devices likely drove growth, led by CGMs, cardiac devices and TMVR system approval. Nutrition and EPD segments are expected to post modest to solid year-over-year revenue gains. Abbott Laboratories (ABT) is slated to report second-quarter 2025 results on July 17, before the opening bell.The company delivered adjusted earnings per share (EPS) of $1.09 in the last quarter, ...